Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

13.59
+1.199.60%
Post-market: 13.840.2500+1.84%19:58 EDT
Volume:5.38M
Turnover:72.82M
Market Cap:1.21B
PE:-4.04
High:13.90
Open:13.59
Low:12.85
Close:12.40
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:1.79
T/O Rate:7.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:24.91
PE(LYR):-4.28

Loading ...

Kura Oncology (KURA) Receives a New Rating from a Top Analyst

TIPRANKS
·
Jul 20

Kura Oncology Announces Availability of Press Release on Darlifarnib-cabozantinib RCC Data Update

Reuters
·
Jul 14

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

GlobeNewswire
·
Jul 14

Kura Oncology Grants Inducement Stock Options for 68,750 Shares at $10.78 Each

Reuters
·
Jul 03

Kura Oncology Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Kura Oncology Price Target Maintained With a $24.00/Share by Citizens

Dow Jones
·
Jun 15

Wedbush Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
Jun 15

Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)

TIPRANKS
·
Jun 13

Kura Oncology posts EHA investor deck detailing ziftomenib AML clinical update

Reuters
·
Jun 12

BUZZ-Kura Oncology up as leukemia drug shows strong survival in early- to mid-stage trial

Reuters
·
Jun 11

Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients

MT Newswires Live
·
Jun 11

Kura Oncology reports 94% 12-month survival in KOMET-007 trial of ziftomenib plus 7+3 in newly diagnosed NPM1-mutant AML

Reuters
·
Jun 11

Kura Oncology - Ziftomenib 600 Mg Once-Daily Plus 7+3 Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
Jun 11

Kura Oncology and Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination in Newly Diagnosed Aml

THOMSON REUTERS
·
Jun 11

Kura Oncology - Reports 12-Month Os Rate of 94% in Npm1-M Aml, 71% in Kmt2a-R Aml

THOMSON REUTERS
·
Jun 11

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

GlobeNewswire
·
Jun 11

Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH), Kura Oncology (KURA) and Hyperion DeFi (HYPD)

TIPRANKS
·
Jun 08

Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer

TIPRANKS
·
Jun 06

Kura Oncology grants 53,000 inducement stock options at $9.04 per share

Reuters
·
Jun 05